Why is This Biotech Company Baker Bros.’ Top Stock Pick?

Baker Bros. Advisors, managed by – you guessed it – Julian and Felix Baker, had quite the second quarter this year. As seen on our list of best performing hedge funds, Baker Bros. Advisors was the second most successful hedge fund over this time period, at least in terms of total returns. The fund’s 13F portfolio, which is reported to the SEC, returned a whopping 15.8% between March 31st and June 30th, and is currently valued to be worth a little over $4.2 billion. With a focus on biotechnology companies, it is understandable how the New York-based hedge fund was able to generate such significant value for its investors over such a little period of time, but it’s also possible for individuals to have this kind of success. Without further ado, here is the top stock pick in Baker Bros.’ 13F portfolio.

Pharmacyclics, Inc. (NASDAQ:PCYC)

Pharmacyclics, Inc. (NASDAQ:PCYC)

Accounting for a 14.7% stake in the hedge fund, Pharmacyclics has returned 325.9% since the start of 2012, and with a market capitalization above $4 billion, this isn’t your typical small-fry biotech stock. The company develops drugs that can be used to treat a variety of ailments including cardiovascular disease and certain cancers. Pharmacyclics’s ace in the hole, however, is its work with texaphyrin-based technology, which is molecular in nature, and can be manipulated by x-ray light to remove cancerous tissue in a patient’s body.

The company also has a solid amount of products in its drug pipeline that have yet to be approved by the FDA, but have enormous potential. The most important is Ibrutinib, a collaborative effort with Janssen Pharmaceuticals, which is a subsidiary of Johnson & Johnson (NYSE:JNJ). The drug is a BTK inhibitor that can be used to treat a variety of cancers, including chronic lymphocytic leukemia, multiple myeloma, mantle cell lymphoma, and diffuse large B-cell lymphoma.

Last year, Ibrutinib was moderately successful in its phase II trials for the treatment of chronic lymphocytic leukemia (CLL), with 7 out of every 10 patients reporting a positive response to the drug. More importantly, Pharmacyclics also announced in August that Ibrutinib was moving in the right direction with regards to its usage to treat mantle cell lymphoma (MCL). The company added its fifth patient to its trial group, automatically prompting a $50 million payment from Johnson & Johnson’s Janssen Pharmaceuticals.

As of this writing, however, Pharmacyclics still has exactly zero FDA-approved products, and its stock price is being propped up by the potential of Ibrutinib’s successful completion of phase III trials. From a valuation standpoint, the company’s shares look to be overbought nearly anyway you look at it. Pharmacyclics has a Price-to-Earnings ratio of 446.1X, far above peers like Cell Therapeutics Inc. (NASDAQ:CTIC), Merck & Co., Inc. (NYSE:MRK), and Valeant Pharmaceuticals Int. (NYSE:VRX). Even when growth is factored into the equation – EPS has grown by 129.2% over the past 12 months – the stock still looks to be overvalued, as it trades at a ridiculous PEG ratio of over 2,000, compared to others in the industry: Merck (4.4), Valeant Pharmaceuticals (16.7), and Cell Therapeutics (n/a). The latter is not expected to generate any significant earnings over the next five years.

While these metrics are measurements of how investors are valuing Pharmacyclics based on its past and foreseeable earnings, they do not take into account the entirety of profit windfalls that could occur from an FDA approval of Ibrutinib in both its CLL and MCL forms.

It appears that many in the hedge fund industry are buying Pharmacyclics based on Ibrutinib’s potential alone, as 15 hedge funds held shares of the company at the end of the second quarter. The most notable bulls were Cliff Asness, Richard Driehaus, and D.E. Shaw. A few fund managers, including Israel Englander and George Soros, closed out their positions in the stock during this time as well, likely because Pharmacyclics’s hypothetical profits were trading at levels much too expensive for their tastes. For a complete look at the hedge fund industry’s sentiment toward this stock, continue reading here

blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

10 Covers of Popular Songs that are Better than the Originals

Must See TV: The 9 Most Anticipated Shows of 2015

The 15 Biggest Box Office Bombs of All Time

10 Things The World Can’t Stand About Americans

Picture Perfect: The 6 Smartphones with the Best Cameras

The 10 Best Countries To Work In the World

A Profitable Day At The Track: 5 Tips For Betting On Horses

Tearing You Apart: 6 Bad Habits That Ruin Relationships

Learning on the Job: The 6 Biggest Mistakes Parents Make

Shopaholics Rejoice: The 12 Biggest Malls in the World

Fright Night: 10 Horror Movies Based on True Stories

Mach Mania: The 10 Fastest Jets in the World

Military Heavyweights: The 10 Countries with the Most Tanks

All In: The 7 Richest Poker Players in the World

Abracadabra: The 10 Best Magicians in the World

The 10 Richest Asian Countries in the World in 2014

Eyes in the Sky: 10 Things You Need to Know About Drones

Rising Stars: The 6 Best Silicon Valley Startups

Military Muscle: The 5 Most Advanced Armies in South America

All that Glitters: The 7 Most Luxurious Jewelry Brands in the World

5 Things You Didn’t Know About ISIS but Should

Empowering Your Money: The 5 Best Energy Stocks to Invest In

The 11 Best Android Apps You Can’t Get on iOS

The 10 Most Important International Conflicts in 2014

Mood Enhancers: The 20 Most Uplifting Songs of all Time

Lover Beware: The 8 Countries that Cheat the Most

Breath of Fresh Air: The 25 Countries with the Best Air Quality on the Planet

Singles Beware: The 8 Worst Mistakes Made on First Dates

Healthy and Happy: The 10 Countries with Lowest Healthcare Costs

The 6 Best Company Team Building Activities to Build Workplace Camaraderie

Ships Ahoy: The 10 Busiest Shipping Ports in the World

10 Productivity Tips to Save You Time and Help You Do More With Less

Grab a Bite: The Most Popular Fast Food Restaurants in America

Friday Night Thirst: The 10 Most Popular Cocktails in the World

The 6 Greatest Unsolved Mysteries We May Never Figure Out

7 Useless Products You Never Should’ve Bought

The 5 Reasons Why You’re Single and Miserable

The 7 Most Addictive Foods in the World We Can’t Stop Eating (Even Though We Should)

5 Amazing Places You Can Swim with Dolphins

The Top 7 Most Livable Countries In The World

The 10 Most Expensive Baseball Cards Ever Pulled From A Pack

The 5 Easiest Second Languages to Learn for English Speakers

Silver Spoon: The 6 Richest Families in the World

The 20 Countries with the Largest Prison Populations in the World

The Top 10 Richest Actors in the World

The 10 Best Airline Stocks to Invest In Before They Fly Too High

Burger Kings: The 10 Most Expensive Burgers in the World

The 10 Most Ethnically Diverse Countries in the World

The 10 Most Exclusive Credit Cards in the World

The 10 Most Expensive Cruise Ships in the World

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!